Psoriasiform and lichenoid eruptions as a potential harbinger of bullous dermatoses in the setting of immune checkpoint inhibitors: a case series
Ahearn EL, Belzer A, Cohen SR, Leventhal JS, Deverapalli SC. Psoriasiform and lichenoid eruptions as a potential harbinger of bullous dermatoses in the setting of immune checkpoint inhibitors: a case series. International Journal Of Dermatology 2022, 62: e411-e414. PMID: 36271737, DOI: 10.1111/ijd.16464.Peer-Reviewed Original ResearchCutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management
Pach J, Leventhal J. Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management. Critical Reviews In Immunology 2022, 42: 1-20. PMID: 37022356, DOI: 10.1615/critrevimmunol.2023046895.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsCheckpoint inhibitorsT cellsAdverse eventsCutaneous immune-related adverse eventsImmune checkpoint inhibitor therapyInhibition of T cellsOveractivation of T cellsCheckpoint inhibitor therapyImmune checkpoint inhibitorsCutaneous adverse eventsStevens-Johnson syndromeCutaneous autoimmune diseasesToxic epidermal necrolysisPre-existing diseaseLife-threatening eruptionsInhibitor therapyTreatment interruptionImmune dysregulationImmune surveillanceMaculopapular eruptionEpidermal necrolysisAutoimmune diseasesBullous dermatosisAntitumor activity